Shilpa Medicare LimitedSHILPAMEDNSE
Amalgamation
As filed · Amalgamation/Merger
DistressDeterioratingCriticalmateriality 98 out of 100
What happened
FactAmalgamation/Merger. Limited, its holding Company, has received approval from the NCLT, Bengaluru Bench, through an order dated. The final order has been uploaded on the NCLT website, accessible as on 5th March 2026.
Why it matters
CapitSignal interpretationOnce an insolvency process is admitted, control of the company passes from the board to a resolution professional and equity ranks last in any recovery.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedEarlierQ2 FY26
We will try to monetize all these investments.
NowQ2 FY26
We should be doing another about INR75 crores to INR100 crores from here on.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement indicated a general intention to monetize investments, while the current statement specifies a future capex target of INR75 to INR100 crores, suggesting a delay in the timeline for achieving these goals.confidence 90%
Watch next
Fact- Admission or rejection of the application by the tribunal
- Appointment of a resolution professional
- Claims admitted against the company
- So we are expecting to start our clinical study, Phase III clinical study, in Q4 FY '26. (management committed by Q4 FY26)
- We should be doing another about INR75 crores to INR100 crores from here on. (management committed by FY26)
Evidence
- NCLT order on merger of Shilpa Therapeutics Private Limited a wholly owned subsidiary with Shilpa Media Limited(opens the original filing in a new tab)
- Earlier statement · Q2 FY26
- Latest statement · Q2 FY26
- Earlier statement · Q2 FY26
How CapitSignal classified this
- Reasoning:
- INSOLVENCY base 93; +5 quantified amount; explicit insolvency/default evidence present; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%